Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30713074 | 0.84 | CYP2C19 (0.36) | MALT1NPC1RAB9A | |
| SCHEMBL27117270 | 0.81 | MALT1 (0.39) | MALT1TRPA1TRPV1SMN1; SMN2 | |
| Pyridine SCHEMBL27120148 | 0.77 | MALT1 (0.36) | MALT1TRPA1TRPV1SMN1; SMN2 | |
| SCHEMBL31690628 | 0.71 | MALT1 (0.43) | MALT1TRPA1TRPV1SMN1; SMN2 | |
| SCHEMBL28966441 | 0.71 | MALT1 (0.43) | MALT1TRPA1TRPV1SMN1; SMN2 | |
| SCHEMBL23005388 | 0.70 | MALT1 (0.42) | MALT1TRPA1TRPV1SMN1; SMN2 | |
| SCHEMBL10300026 | 0.70 | MALT1 (0.43) | MALT1TRPA1TRPV1SMN1; SMN2 | |
| SCHEMBL29386992 | 0.69 | HSD11B1 (0.40) | TRPA1TRPV1 | |
| SCHEMBL30301254 | 0.69 | MALT1 (0.43) | MALT1TRPA1TRPV1SMN1; SMN2 | |
| SCHEMBL6909143 | 0.69 | MALT1 (0.43) | MALT1TRPA1TRPV1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117412965-A | Novel process for the preparation of anthranilic diamides | PI工业有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20220298136-A1 | PROCESS FOR SYNTHESIS OF PYRAZOLIDINONE COMPOUNDS | GHARDA CHEMICALS LIMITED (IN) | 2022-09-22 | — | — | US | disclosed |
| EP-4003962-A1 | PROCESS FOR SYNTHESIS OF PYRAZOLIDINONE COMPOUNDS | Gharda Chemicals Limited (IN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021033166-A1 | PROCESS FOR SYNTHESIS OF PYRAZOLIDINONE COMPOUNDS | GHARDA CHEMICALS LIMITED (IN) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298136-A1 | PROCESS FOR SYNTHESIS OF PYRAZOLIDINONE COMPOUNDS | DHPS, AZI2, CMPK1 | MALT1 4707/4885TRPA1 4230/4885GLA 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.